Breaking News, Collaborations & Alliances

Andelyn Biosciences, UMass Partner on Cockayne Syndrome

The cell and gene therapy CDMO was chosen by UMass Chan Medical School to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Andelyn Biosciences, a cell and gene therapy contract development and manufacturing organization (CDMO), has been selected by UMass Chan Medical School to use its suspension AAV Curator Platform to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome. The nonprofit patient-advocacy organization, Riaan Research Initiative, has provided the largest known donation ever made toward the development of a treatment for Cockayne syndrome. The gift from Riaan Research Initiative and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters